August 13, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) will join Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. The company will explore access to MSK’s expertise and resources, including GMP manufacturing services, Investigational New Drug (IND) Application preparation and submission and regulatory strategy support to expedite Bria-OTS+ development.
BriaCell’s President and CEO, Dr. William V. Williams, expressed honor in collaborating with MSK’s experts, citing their expertise and resources as ideal for accelerating their immunotherapy platform.
MSK’s Director of Technology Development & Licensing, Eileen Flowers, PhD, welcomed BriaCell into the program.
BriaCell’s Chief Scientific Officer, Dr. Miguel Lopez-Lago, sees the participation as a step toward advancing cancer care.
BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies.
Contact Information:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
Source: BriaCell Therapeutics Corp.
